EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience

Alexander Wallace iD, Oliver Zhou, Minh-Nguyet Hoang, Gabriella Porter, Claudia Padilla, Cindy Marshall

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-04 · 18 (2)

DOI: 10.1002/dad2.70377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, online erschienen am 21.05.2026. Verfasst von Alexander Wallace und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Iowa Hospitals and Clinics Iowa City Iowa USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Lecanemab has demonstrated both safety and efficacy in clinical trials; however, routine clinical data are sparse. We contribute to the growing body of real‐world safety data, with a special focus on amyloid‐related imaging abnormalities (ARIA). METHODS We conducted a retrospective chart review of 146 patients treated with lecanemab according to appropriate‐use recommendations at a specialty memory center clinic. RESULTS Real‐world safety and efficacy data closely resemble published data in the Clarity‐AD trial. Thirty‐three patients (23%) discontinued treatment; all remaining patients completed at least 12 months of treatment. We observed a positive trend toward increasing ARIA edema/effusion (ARIA‐E) with increasing mean arterial pressure and a mean amyloid clearance of −90.6 at 18 months. DISCUSSION When used according to appropriate‐use recommendations, lecanemab is as safe as reported in the Clarity‐AD trial. Further investigation into real‐world data is necessary for a more complete evaluation of lecanemab's safety and efficacy.

Schlagwörter

Stichwörter der Autor:innen

APOE ε4Alzheimer's diseaseamyloid plaque clearanceamyloid‐related imaging abnormalities (ARIA)anti‐amyloid monoclonal antibodieslecanemabmagnetic resonance imagingreal‐world data

Autor:innen und Institutionen

  • University of Iowa Hospitals and Clinics Iowa City Iowa USA.
  • Texas A&M College of Medicine Bryan Texas USA.
  • Baylor University Medical Center Dallas Texas USA.
  • Baylor AT&T Memory Center Dallas Texas USA.

ORCID-Profile: Alexander Wallace

Zitieren

APA

Wallace, A., Zhou, O., Hoang, M. N., Porter, G., Padilla, C., & Marshall, C. (2026). Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(2). https://doi.org/10.1002/dad2.70377

Vancouver

Wallace A, Zhou O, Hoang MN, Porter G, Padilla C, Marshall C. Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(2). doi:10.1002/dad2.70377

BibTeX
@article{Wallace2026,
  author = {Wallace, Alexander and Zhou, Oliver and Hoang, Minh-Nguyet and Porter, Gabriella and Padilla, Claudia and Marshall, Cindy},
  title = {Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience},
  journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
  year = {2026},
  volume = {18},
  number = {2},
  doi = {10.1002/dad2.70377}
}
Kostenlos starten →